Merck & Co. (NYSE:MRK) said it halted a mid‑stage trial of MK‑1167 for mild‑to‑moderate Alzheimer’s after enrolling about 350 patients and closed the study in June for business reasons with no safety concerns, while analysts remain bullish ahead of its Aug. 4 Q2 earnings call.
Previous Week Recap
- Merck Halts MK-1167 Trial: Merck halted a mid-stage trial of MK-1167 for mild-to-moderate Alzheimer’s after enrolling ~350 patients; study closed in early June 2026 for business reasons; no safety issues reported.
- Merck Q2 2026 Call Scheduled: Merck & Co. (MRK) will hold its Q2 2026 sales and earnings call for investors and analysts on Aug. 4, 2026 at 9:00 a.m. ET, covering the quarter's performance.
- Analysts Maintain Buys On Merck: Scotiabank kept Sector Outperform on Merck (MRK) and raised its target to $155. Bank of America kept Buy and lifted its target to $141.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.